Swiss scientists have created a novel blood-filtering device that removes the toxic proteins linked to Alzheimer’s disease—beta-amyloid and tau—from the bloodstream. These proteins build up in the brain and contribute to cognitive decline, but early clinical studies suggest that reducing their levels can improve memory and thinking abilities within weeks.
Nanofilter Technology Targets Existing Alzheimer’s Proteins
The technology uses nanoscale filters that capture harmful proteins while allowing healthy blood cells and molecules to pass through. As filtered blood circulates back through the body, natural exchanges across the blood-brain barrier help lower protein concentrations in the brain. Unlike many existing medications that focus on slowing protein production, this approach targets and removes proteins that have already accumulated. Patients typically undergo two outpatient treatments per week for eight weeks, followed by monthly maintenance sessions.
Although initial results are encouraging, many insurers still consider the therapy experimental and often decline coverage. Supporters note that the treatment costs significantly less than the long-term care associated with Alzheimer’s disease, which can exceed $80,000 annually in the U.S. They argue that limited insurance coverage may prevent patients from accessing a potentially groundbreaking therapy and place additional financial strain on affected families.
Read the original article on: o sao paulo
Read more: Meet the astronauts of Artemis III as they prepare for NASA’s most ambitious journey to the Moon